Hospira Recalls Methotrexate Injection Due to Embedded Glass Particles
Hospira Inc. is recalling Methotrexate Injection vials because visible particles embedded in the glass neck may dislodge into the solution.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II and involves a structural defect (embedded glass particles) in a cytotoxic drug, which poses a significant risk of injury if particles dislodge into the solution.
Plain-English summary
Hospira Inc. is recalling Methotrexate Injection, USP, 25 mg/mL, 40 mL Single Dose Vials. The recall affects 34,572 vials with lot number Y064457AA and an expiration date of October 2013. The product was distributed nationwide, including Puerto Rico and Guam, as well as internationally to Australia, Belgium, Canada, France, Germany, Korea, Malaysia, New Zealand, Norway, Pakistan, Philippines, Portugal, Singapore, Sweden, Thailand, and Vietnam.
The recall was initiated due to visible particles embedded in the glass located at the neck of the vial. There is a potential for the product to come into contact with these embedded particles, which may become dislodged into the solution. This recall is classified as FDA Class II.
Healthcare providers and patients should stop using the affected vials and contact Hospira Inc. for further instructions. The recall also includes other affected lots of Carboplatin Injection, Cytarabine Injection, and Paclitaxel Injection due to the same defect.
The recalled product
- Product
- METHOTREXATE (METHOTREXATE)
- Brand
- METHOTREXATE
- Manufacturer
- Hospira Inc.
- Category
- Drug — Antineoplastic
- Affected units
- 34,572
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- lot number Y064457AA
- exp OCT 2013 Rest of world lot numbers: list M4457A001
- lot number Y054457AB
- exp SEP 2013
Distribution
Part of a larger recall action
This product is one of 4 recalled by Hospira Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 4 products in this recall →Related recalls
Same brand · METHOTREXATE
- ModerateCardinal Health Recalls Methotrexate Injection Due to Temperature Excursions
FDA (Drugs) · 2021-06-02
Same manufacturer · Hospira Inc.
See all →- CriticalHospira Recalls Dextrose Injection Syringes Due to Human Hair Particulate
FDA (Drugs) · 2017-05-31
- ModerateHospira Recalls Minibore Extension Sets Due to Solvent Occlusion
FDA (Devices) · 2017-01-18
- LowHospira Recalls Lidocaine and Dextrose Injection for Stability Failures
FDA (Drugs) · 2016-12-14
- SevereHospira Recalls Fentanyl Citrate Injection Ampules Due to Broken Tips
FDA (Drugs) · 2016-11-30
- HighHospira Symbiq Infusion Pump Recall for White Screen Safety Shutdown
FDA (Devices) · 2016-11-16
Same hazard · glass particles
See all →- SevereFresenius Kabi Recalls Tyenne Injection Due to Glass Particles
FDA (Drugs) · 2026-09-02
- HighDexamethasone and moxifloxacin injection recalled over glass-like particulate matter
FDA (Drugs) · 2026-01-14
- HighTri-Moxi intraocular injection recalled over glass-like particulate matter
FDA (Drugs) · 2026-01-14
- HighIntraocular injection syringes recalled over glass-like particulate matter
FDA (Drugs) · 2026-01-14
- ModerateTestosterone Pellet 100 mg recalled due to glass particle contamination
FDA (Drugs) · 2025-05-14